Applied Therapeutics, Inc.(APLT)Earnings, Financials & Key Ratios
APLT•NASDAQ
$0.10
Price updated Jun 27, 2026
AboutApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Show more
- Revenue$455K-95.4%
- EBITDA-$104M-61.6%
- Net Income-$106M+11.8%
- EPS (Diluted)-0.76+46.5%
- Gross Margin-10612.97%-2315.2%
- EBITDA Margin-22922.64%-3449.5%
- Operating Margin-22922.86%-3449.5%
- Net Margin-23214.07%-1837.0%
- ROE-529.97%
APLT Price & Volume
Applied Therapeutics, Inc. (APLT) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Outpaces Commercial Revenue Growth
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Regulatory binary outcome risk
"Applied Therapeutics remains a high-risk, pre-commercial biotechnology entity characterized by a structural reliance on external capital to fund its late-stage clinical pipeline. While the company attempts to navigate the FDA regulatory landscape, the lack of a sustainable commercial revenue stream—evidenced by a nominal $1.0 million in 2025Q3 revenue—creates significant uncertainty regarding long-term viability. Investors should monitor the company's ability to manage its liquidity, as the rapid erosion of the asset base and negative equity position suggest that further shareholder dilution remains a primary risk factor."
Verdict Logic
the company's current ratio has compressed to 0.96 as of 2025Q3, indicating that current liabilities now exceed current assets and leaving the firm with limited financial flexibility.
APLT Growth Metrics
Applied Therapeutics, Inc. (APLT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM573.93%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM90.32%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM93.64%
Return on Capital
10 Years-221.43%
5 Years-257.99%
3 Years-363.62%
Last Year-484.59%
Peers Comparison
Key metrics vs top competitors for Applied Therapeutics, Inc. (APLT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.10 | $14.86M | -0.14 | -95.45% | -23214.07% | -529.97% | — | |
| $30.77 | $3.03B | -5.28 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $84.43 | $7B | 10.85 | 114.51% | -22.58% | — | — | |
| $372.25 | $10.97B | 54.42 | 33.94% | 53.92% | 19.25% | — |
Compare APLT vs Peers
Applied Therapeutics, Inc. (APLT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when APLT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
APLT Frequently Asked Questions
Applied Therapeutics, Inc. (APLT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Applied Therapeutics, Inc.'s revenue?
Applied Therapeutics, Inc. (APLT) reported $1.0M in revenue for fiscal year 2024.
How fast is Applied Therapeutics, Inc. growing?
Applied Therapeutics, Inc. (APLT) saw revenue decline by 95.4% over the past year.
Is APLT profitable?
Applied Therapeutics, Inc. (APLT) reported a net loss of $18.1M for fiscal year 2024.
Dividend & Returns
What is APLT's return on equity?
Applied Therapeutics, Inc. (APLT) has a return on equity (ROE) of -530.0%. Negative ROE indicates the company is unprofitable.
What is Applied Therapeutics, Inc.'s free cash flow?
Applied Therapeutics, Inc. (APLT) had negative free cash flow of $86.8M in fiscal year 2024, likely due to heavy capital investments.